Zhang Sujuan, Yuan Lijin, Wang Yunliang, Sun Zhe
Sujuan Zhang, Department of Outpatient, Baoding No.1 Central Hospital, Baoding, Hebei, 071000, China.
Lijin Yuan, Department of Obstetrics, East Hospital of Baoding No.1 Central Hospital, Baoding, Hebei, 071000, China.
Pak J Med Sci. 2022 May-Jun;38(5):1376-1381. doi: 10.12669/pjms.38.5.4641.
To investigate the effect of Fu Yan Qing prescription on sequelae of pelvic inflammatory disease of accumulation of dampness heat and blood stasis type.
Total 80 patients with sequelae of sequelae of pelvic inflammatory disease of accumulation of dampness heat and blood stasis type were admitted to Baoding No.1 Central Hospital from December, 2018 to April, 2020 and divided into two groups according to the random number table, with 40 cases in each group. Patients in the control group were treated with conventional western medicine, while patients in the observation group were treated with Fu Yan Qing prescription orally. The clinical efficacy, the changes of traditional Chinese medicine (TCM) syndromes, local sign scores, visual analog scale (VAS) of pain, pelvic mass size, pelvic fluid volume and uterine blood flow parameters of the two groups before and after treatment were observed and compared, and the safety of the two groups was evaluated.
The total efficacy after treatment in the observation group was 87.5%, which was significantly higher than that of 67.5% in the control group (0.05). The TCM syndrome scores, local signs scores, pain scores, size of pelvic mass and pelvic effusion in both groups decreased significantly after treatment (0.05), PSV indexes of the two groups were significantly increased after treatment (0.05), and these changes were even more pronounced in the observation group (0.05). Compared with before treatment, PI and RI indexes of the observation group were significantly decreased after treatment (<0.05). The observation group experienced an adverse reaction in 7.5% cases considerably lower than the 27.5% of the control group (p<0.05).
Fu Yan Qing prescription is a safe and reliable treatment for patients with sequelae of pelvic inflammatory disease of accumulation of dampness heat and blood stasis type. It is worth promotion in clinical practice.
探讨妇炎清方对湿热瘀结型盆腔炎后遗症的影响。
选取2018年12月至2020年4月在保定市第一中心医院收治的80例湿热瘀结型盆腔炎后遗症患者，按随机数字表法分为两组，每组40例。对照组采用常规西药治疗，观察组采用妇炎清方口服治疗。观察比较两组治疗前后的临床疗效、中医证候变化、局部体征评分、疼痛视觉模拟量表（VAS）评分、盆腔包块大小、盆腔积液量及子宫血流参数，并评价两组的安全性。
观察组治疗后总有效率为87.5%，显著高于对照组的67.5%（P<0.05）。两组治疗后中医证候评分、局部体征评分、疼痛评分、盆腔包块大小及盆腔积液均显著降低（P<0.05），两组治疗后PSV指标均显著升高（P<0.05），且观察组变化更明显（P<0.05）。观察组治疗后PI和RI指标较治疗前显著降低（P<0.05）。观察组不良反应发生率为7.5%，明显低于对照组的27.5%（P<0.05）。
妇炎清方治疗湿热瘀结型盆腔炎后遗症安全可靠，值得临床推广应用。
